News2021-11-08T15:40:15-05:00

Latest Isologic News

News, Insight, Education – Welcome to the Isologic Blog

22Jun, 2022

Telix and Isologic sign License and Distribution Agreement for Illuccix® for Canada

By |June 22nd, 2022|Categories: In the press, Isologic News|0 Comments

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed a license and distribution agreement with Isologic Innovative Pharmaceuticals Ltd (Isologic) for the commercialisation of Telix’s investigational prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga-68 gozetotide injection), also known as 68Ga-PSMA-11 injection, for the Canadian [...]

15Jun, 2022

Isologic Innovatives pharmaceuticals seminar-SNMMI annual conference- June 2022

By |June 15th, 2022|Categories: In the press, Isologic News|0 Comments

Our scientific event organized on June 13, 2022 during the SNMMI annual conference was a great success, We thank all the experts who accepted our invitation and took part in this seminar dedicated to PET imaging agents. Two international experts offered an overview of prostate and brain cancer imaging to [...]

1Dec, 2020

CPDC, New acquisition

By |December 1st, 2020|Categories: In the press, Isologic News|0 Comments

Dear customers, We are pleased to announce that Isologic has just completed the acquisition of the FDG Canadian distribution business from Centre for Probe Development and Commercialization (CPDC). As a result, all FDG customers serviced by CPDC are, effective December 1st, serviced by Isologic out of our Toronto (Sunnybrook) facility. [...]

9Jan, 2020

NEW PRODUCT AVAILABLE

By |January 9th, 2020|Categories: Isologic News|0 Comments

Antimony Sulfide Colloid Tc99m injection January 9th, 2020 Dear Valued Customer, It is with great pleasure that we would like to inform you that Isologic has a new product within its portfolio. We are introducing Antimony Sulfide Colloid Tc99m injection. This product is indicated for use as [...]

5Dec, 2019

Gallium-68 generator, Galli Eo®

By |December 5th, 2019|Categories: Isologic News|0 Comments

IRE Elit and Isologic announce the approval of the Gallium-68 generator, Galli Eo®, as a drug in Canada December 5th, 2019 - Fleurus, Belgium & Montreal, Canada: IRE ELIT, Belgian radiopharmaceutical company, has just received the Notice of Compliance (NOC) from Health Canada for its drug Galli [...]

General Nuclear Medicine News

News and Education provided by World Leading Experts

22Jun, 2022

Telix and Isologic sign License and Distribution Agreement for Illuccix® for Canada

By |June 22nd, 2022|Categories: In the press, Isologic News|0 Comments

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed a license and distribution agreement with Isologic Innovative Pharmaceuticals Ltd (Isologic) for the commercialisation of Telix’s investigational prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga-68 gozetotide injection), also known as 68Ga-PSMA-11 injection, for the Canadian [...]

15Jun, 2022

Isologic Innovatives pharmaceuticals seminar-SNMMI annual conference- June 2022

By |June 15th, 2022|Categories: In the press, Isologic News|0 Comments

Our scientific event organized on June 13, 2022 during the SNMMI annual conference was a great success, We thank all the experts who accepted our invitation and took part in this seminar dedicated to PET imaging agents. Two international experts offered an overview of prostate and brain cancer imaging to [...]

1Dec, 2020

CPDC, New acquisition

By |December 1st, 2020|Categories: In the press, Isologic News|0 Comments

Dear customers, We are pleased to announce that Isologic has just completed the acquisition of the FDG Canadian distribution business from Centre for Probe Development and Commercialization (CPDC). As a result, all FDG customers serviced by CPDC are, effective December 1st, serviced by Isologic out of our Toronto (Sunnybrook) facility. [...]

1Mar, 2018

First diagnostic radiotracer for early diagnosis of Alzheimer’s disease approved in Canada

By |March 1st, 2018|Categories: In the press|0 Comments

PIRAMAL IMAGING SA AND ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS ANNOUNCE COMMERCIAL APPROVAL OF NEURACEQ™ BY HEALTH CANADA MONTREAL, Feb. 28, 2017 /CNW Telbec Piramal Imaging SA and ISOLOGIC Innovative Radiopharmaceuticals today announce that Health Canada has issued a Notice of Compliance (NOC) [...]

31Jan, 2018

IRE-ELiT S.A. & Isologic Sign Exclusive Agreement

By |January 31st, 2018|Categories: In the press|0 Comments

IRE-ELiT S.A. (Environment & Lifescience Technology) & Isologic signed an exclusive agreement for the distribution of Galli Eo™ 68Ge/ 68Ga generator in Canada FLEURUS, Belgium ; Montreal, Canada ; the 31st January. IRE-ELiT S.A. (Environment & Lifescience Technology) & Isologic Innovative Radiopharmaceuticals, the [...]

14Jan, 2016

ISOLOGIC Acquires Lantheus Canadian Imaging Centres

By |January 14th, 2016|Categories: In the press|0 Comments

ISOLOGIC Acquires Lantheus Canadian Imaging Centres ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS ACQUIRES LANTHEUS MEDICAL IMAGING CANADIAN RADIOPHARMACEUTICAL CENTRES ISOLOGIC is pleased to announce the completion of an asset purchase agreement for the acquisition of the Canadian radiopharmacy and Gludef manufacturing and [...]

4Jun, 2015

Piramal Announces Strategic Partnership with ISOLOGIC

By |June 4th, 2015|Categories: In the press|0 Comments

PIRAMAL IMAGING ANNOUNCES STRATEGIC PARTNERSHIP WITH ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS FOR EXCLUSIVE COMMERCIALIZATION OF NEURACEQ IN CANADA BOSTON, June 4, 2015 Piramal Imaging SA and ISOLOGIC Innovative Radiopharmaceuticals today announce the companies have entered into a strategic partnership and licensing agreement [...]

Go to Top